Sabitlenmiş Tweet
The moral panic about GLP-1 rebound. A new note on my S*bstack.
English
Natasha Loder 🦋🐝
29.2K posts
Natasha Loder 🦋🐝
@natashaloder
Health Editor, The Economist
London, England Katılım Şubat 2009
3.9K Takip Edilen20.8K Takipçiler
Natasha Loder 🦋🐝 retweetledi
With ozempic going generic in India, China, Brazil this weekend, re-upping this piece with @natashaloder
open.substack.com/pub/singerp/p/…
English
And of course all of this subject to caveats that this isn't an RCT but is an attempt to emulate one.
English
Whiplash implies a sudden sharp reversal which might lead doctors to want to warn patients about an acute risk when coming off these drugs. This, though, seems to say that if you take 6 months off then there is a 4% increase in the risk of heart attack, stroke and death.
English
Really useful study.
I hope the phrase "metabolic whiplash" doesn't catch on for the decline in cardiac protection that happens when you stop these drugs. Seems to me @EricTopol that it is more like a gradual and cumulative risk, rather than a spike?
Thread Reader App@threadreaderapp
@natashaloder @zalaly @Biostayan @washumedicine @WashU @VAResearch @natashaloder Hi, here is your unroll: threadreaderapp.com/thread/2034323… Talk to you soon. 🤖
English
English
The heavy lifting here was done by the amazing @biostayan
Press release by the wonderful Shawn Ballard: medicine.washu.edu/news/stopping-…
@WashUMedicine @WashU @VAResearch
Paper:
bmjmedicine.bmj.com/content/5/1/e0…
English
About 1 in 8 U.S. adults has taken a GLP-1 drug. But 36–81% of users stop within the first year. Most studies have focused on weight regain after stopping. We focused on what happens to the heart.
English
Natasha Loder 🦋🐝 retweetledi
The reckless campaign against Iran will weaken America’s president. That will make him angry. Be warned: he makes a very bad loser econ.st/4lA7lEQ
English
A Lancet review says chatbots may actively encourage delusional thinking in vulnerable users.
This piece digs into why we urgently need proper trials and guardrails.
open.substack.com/pub/overmatter…
English
Were early humans plastered because they were planters? Or civilised because they were sozzled? We trace the history of alcohol, a substance that has shaped civilisation as we know it economist.com/christmas-spec…
English
Alcohol has shaped human history, from our ancestors’ descent from the trees to the formation of civilisations. But today a new wariness of booze is spreading. Natasha Loder, The Economist’s health editor, explores whether we have reached peak alcohol: econ.st/472QC70
English
Natasha Loder 🦋🐝 retweetledi
GLP-1 drugs for extending healthspan?
Intriguing but we're a long way off from evidence
Discussed at length in Super Agers as a candidate drug beyond lifestyle + factors @TheEconomist
gift link
economist.com/science-and-te…
English
English
We're expanding London's network of cycleways, making streets safer & enabling more people to choose healthy & sustainable ways to travel.
Great to see the new protected bike lanes being built on Westbourne Terrace in @CityWestminster.
👏 @AdamHug Max Sullivan & team with @TfL
English
Your drinking problem started ten million years ago.
Find out why and what the future of drinking might look like, and come argue with me in the comments.
overmatter.substack.com/p/ten-million-…
English
Find out more about the radio show, the essay behind it, and come and argue with me about the future of drinking: open.substack.com/pub/overmatter…
English
My NPR interview on "Are we breaking up with booze?" with @krysboydthink with Think. We went deep on evolution, Gen Z's drinking habits, functional drinks, and GABA Labs.
English
Find out more about the radio show, the essay behind it, and come and argue with me about the future of drinking.
open.substack.com/pub/overmatter…
English
My NPR interview on "Are we breaking up with booze?" for NPR @thinkKERA with @KrysBoydThink just went live. We went deep on evolution, Gen Z's drinking habits, functional drinks, and @LabsGaba
English
Find out more about this story on Overmatter, my Substack. open.substack.com/pub/overmatter…
English
Actually this is very much a drill.
It is a risky regulatory experiment to allow these treatments on to the market and then figure out later on if they work.
Paul White Gold Eagle@PaulGoldEagle
BREAKING: Japan Approves World’s First iPSC Stem Cell Therapy for Parkinson’s Disease. This is not a drill. This is history. Japan’s Health Ministry has officially approved two iPS cell therapies: Amchepry for Parkinson’s and ReHeart for severe heart failure. Based on Nobel Prize-winning research, these treatments use reprogrammed stem cells to regenerate damaged dopamine neurons in the brain. Seven patients were treated. Four showed significant improvement. No major side effects. Available to patients by summer 2026. 10 million people worldwide have Parkinson’s. The cure is no longer theoretical.
English